Prolonged Ketamine Effects in Sp4 Hypomorphic Mice: Mimicking Phenotypes of Schizophrenia

PLoS ONE

Volumn 8, Issue 6, 2013, Pages

  Ji, Baohu ^a   Wang, Xin ^b   Pinto Duarte, Antonio ^b,d,e   Kim, Minjung ^a   Caldwell, Sorana ^a,c   Young, Jared W ^a,c   Behrens, Margarita M ^b   Sejnowski, Terrence J ^b   Geyer, Mark A ^a,c   Zhou, Xianjin ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b SALK INSTITUTE FOR BIOLOGICAL STUDIES   (United States)

^c VA SAN DIEGO HEALTHCARE SYSTEM   (United States)

^d INSTITUTO DE MEDICINA MOLECULAR   (Portugal)

^e UNIVERSITY OF LISBON   (Portugal)

Author keywords

[No Author keywords available]

Indexed keywords

GLUTAMATE DECARBOXYLASE 67; KETAMINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR 1; TRANSCRIPTION FACTOR SP4; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; SP4 PROTEIN, MOUSE;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN CORTEX; CHEMOSENSITIVITY; CONTROLLED STUDY; DRUG RESPONSE; ELECTROENCEPHALOGRAPHY; FEMALE; GAMMA RHYTHM; GENETIC ASSOCIATION; HIPPOCAMPAL CA1 REGION; IMMUNOHISTOCHEMISTRY; LONG TERM POTENTIATION; MALE; MOUSE; NONHUMAN; PATHOPHYSIOLOGY; PHENOTYPE; PREPULSE INHIBITION; PROTEIN EXPRESSION; SCHIZOPHRENIA; SIGNAL TRANSDUCTION; SP4 GENE; ANIMAL; DISEASE MODEL; GENETICS; METABOLISM;

MUS;

ANIMALS; DISEASE MODELS, ANIMAL; KETAMINE; LONG-TERM POTENTIATION; MICE; PHENOTYPE; RECEPTORS, N-METHYL-D-ASPARTATE; SCHIZOPHRENIA; SIGNAL TRANSDUCTION; SP4 TRANSCRIPTION FACTOR;

EID: 84879162198     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0066327     Document Type: Article

References (51)

1. Luby ED, Cohen BD, Rosenbaum G, Gottlieb JS, Kelley R, (1959) Study of a new schizophrenomimetic drug; sernyl. AMA Arch Neurol Psychiatry 81: 363-369.
2. Moriyoshi K, Masu M, Ishii T, Shigemoto R, Mizuno N, et al. (1991) Molecular cloning and characterization of the rat NMDA receptor. Nature 354: 31-37.
3. Javitt DC, Zukin SR, (1991) Recent advances in the phencyclidine model of schizophrenia. Am J Psychiatry 148: 1301-1308.
4. Krystal JH, Karper LP, Seibyl JP, Freeman GK, Delaney R, et al. (1994) Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch Gen Psychiatry 51: 199-214.
5. Lahti AC, Koffel B, LaPorte D, Tamminga CA, (1995) Subanesthetic doses of ketamine stimulate psychosis in schizophrenia. Neuropsychopharmacology 13: 9-19.
6. Holcomb HH, Lahti AC, Medoff DR, Cullen T, Tamminga CA, (2005) Effects of noncompetitive NMDA receptor blockade on anterior cingulate cerebral blood flow in volunteers with schizophrenia. Neuropsychopharmacology 30: 2275-2282.
7. Malhotra AK, Pinals DA, Adler CM, Elman I, Clifton A, et al. (1997) Ketamine-induced exacerbation of psychotic symptoms and cognitive impairment in neuroleptic-free schizophrenics. Neuropsychopharmacology 17: 141-150.
8. Dalmau J, Gleichman AJ, Hughes EG, Rossi JE, Peng X, et al. (2008) Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies. Lancet Neurol 7: 1091-1098.
9. Iizuka T, Sakai F, Ide T, Monzen T, Yoshii S, et al. (2008) Anti-NMDA receptor encephalitis in Japan: long-term outcome without tumor removal. Neurology 70: 504-511.
10. Gao XM, Sakai K, Roberts RC, Conley RR, Dean B, et al. (2000) Ionotropic glutamate receptors and expression of N-methyl-D-aspartate receptor subunits in subregions of human hippocampus: effects of schizophrenia. Am J Psychiatry 157: 1141-1149.
11. Law AJ, Deakin JF, (2001) Asymmetrical reductions of hippocampal NMDAR1 glutamate receptor mRNA in the psychoses. Neuroreport 12: 2971-2974.
12. Weickert CS, Fung SJ, Catts VS, Schofield PR, Allen KM, et al. (2012) Molecular evidence of N-methyl-D-aspartate receptor hypofunction in schizophrenia. Mol Psychiatry.
13. Mohn AR, Gainetdinov RR, Caron MG, Koller BH, (1999) Mice with reduced NMDA receptor expression display behaviors related to schizophrenia. Cell 98: 427-436.
14. Belforte JE, Zsiros V, Sklar ER, Jiang Z, Yu G, et al. (2010) Postnatal NMDA receptor ablation in corticolimbic interneurons confers schizophrenia-like phenotypes. Nat Neurosci 13: 76-83.
15. Carlen M, Meletis K, Siegle JH, Cardin JA, Futai K, et al. (2011) A critical role for NMDA receptors in parvalbumin interneurons for gamma rhythm induction and behavior. Mol Psychiatry.
16. Heisler LE, Torti D, Boutros PC, Watson J, Chan C, et al. (2005) CpG Island microarray probe sequences derived from a physical library are representative of CpG Islands annotated on the human genome. Nucleic Acids Res 33: 2952-2961.
17. Supp DM, Witte DP, Branford WW, Smith EP, Potter SS, (1996) Sp4, a member of the Sp1-family of zinc finger transcription factors, is required for normal murine growth, viability, and male fertility. Dev Biol 176: 284-299.
18. Zhou X, Long JM, Geyer MA, Masliah E, Kelsoe JR, et al. (2005) Reduced expression of the Sp4 gene in mice causes deficits in sensorimotor gating and memory associated with hippocampal vacuolization. Mol Psychiatry 10: 393-406.
19. Zhou X, Qyang Y, Kelsoe JR, Masliah E, Geyer MA, (2007) Impaired postnatal development of hippocampal dentate gyrus in Sp4 null mutant mice. Genes Brain Behav 6: 269-276.
20. Zhou X, Nie Z, Roberts A, Zhang D, Sebat J, et al. (2010) Reduced NMDAR1 expression in the Sp4 hypomorphic mouse may contribute to endophenotypes of human psychiatric disorders. Hum Mol Genet 19: 3797-3805.
21. Tam GW, van de Lagemaat LN, Redon R, Strathdee KE, Croning MD, et al. (2010) Confirmed rare copy number variants implicate novel genes in schizophrenia. Biochem Soc Trans 38: 445-451.
22. Pinacho R, Villalmanzo N, Lalonde J, Haro JM, Meana JJ, et al. (2011) The transcription factor SP4 is reduced in postmortem cerebellum of bipolar disorder subjects: control by depolarization and lithium. Bipolar Disord 13: 474-485.
23. Zhou X, Tang W, Greenwood TA, Guo S, He L, et al. (2009) Transcription factor SP4 is a susceptibility gene for bipolar disorder. PLoS ONE 4: e5196.
24. Shi J, Potash JB, Knowles JA, Weissman MM, Coryell W, et al. (2010) Genome-wide association study of recurrent early-onset major depressive disorder. Mol Psychiatry.
25. Shyn SI, Shi J, Kraft JB, Potash JB, Knowles JA, et al. (2009) Novel loci for major depression identified by genome-wide association study of Sequenced Treatment Alternatives to Relieve Depression and meta-analysis of three studies. Mol Psychiatry.
26. Greenwood TA, Lazzeroni LC, Murray SS, Cadenhead KS, Calkins ME, et al. (2011) Analysis of 94 candidate genes and 12 endophenotypes for schizophrenia from the Consortium on the Genetics of Schizophrenia. Am J Psychiatry 168: 930-946.
27. Banbury (1997) Mutant mice and neuroscience: recommendations concerning genetic background. Banbury Conference on genetic background in mice. Neuron 19: 755-759.
28. Brody SA, Geyer MA, Large CH, (2003) Lamotrigine prevents ketamine but not amphetamine-induced deficits in prepulse inhibition in mice. Psychopharmacology (Berl) 169: 240-246.
29. Kapur S, Seeman P, (2002) NMDA receptor antagonists ketamine and PCP have direct effects on the dopamine D(2) and serotonin 5-HT(2)receptors-implications for models of schizophrenia. Mol Psychiatry 7: 837-844.
30. Bakshi VP, Tricklebank M, Neijt HC, Lehmann-Masten V, Geyer MA, (1999) Disruption of prepulse inhibition and increases in locomotor activity by competitive N-methyl-D-aspartate receptor antagonists in rats. J Pharmacol Exp Ther 288: 643-652.
31. Homayoun H, Moghaddam B, (2007) NMDA receptor hypofunction produces opposite effects on prefrontal cortex interneurons and pyramidal neurons. J Neurosci 27: 11496-11500.
32. Moghaddam B, Adams B, Verma A, Daly D, (1997) Activation of glutamatergic neurotransmission by ketamine: a novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex. J Neurosci 17: 2921-2927.
33. Cardin JA, Carlen M, Meletis K, Knoblich U, Zhang F, et al. (2009) Driving fast-spiking cells induces gamma rhythm and controls sensory responses. Nature 459: 663-667.
34. Kim M, Soontornniyomkij V, Ji B, Zhou X, (2012) System-wide immunohistochemical analysis of protein co-localization. PLoS One 7: e32043.
35. Rotaru DC, Yoshino H, Lewis DA, Ermentrout GB, Gonzalez-Burgos G, (2011) Glutamate receptor subtypes mediating synaptic activation of prefrontal cortex neurons: relevance for schizophrenia. J Neurosci 31: 142-156.
36. Nicolas MJ, Lopez-Azcarate J, Valencia M, Alegre M, Perez-Alcazar M, et al. (2011) Ketamine-induced oscillations in the motor circuit of the rat basal ganglia. PLoS One 6: e21814.
37. Hunt MJ, Raynaud B, Garcia R, (2006) Ketamine dose-dependently induces high-frequency oscillations in the nucleus accumbens in freely moving rats. Biol Psychiatry 60: 1206-1214.
38. Uhlhaas PJ, Pipa G, Neuenschwander S, Wibral M, Singer W, (2011) A new look at gamma? High- (>60 Hz) gamma-band activity in cortical networks: function, mechanisms and impairment. Prog Biophys Mol Biol 105: 14-28.
39. Brumberg JC, Nowak LG, McCormick DA, (2000) Ionic mechanisms underlying repetitive high-frequency burst firing in supragranular cortical neurons. J Neurosci 20: 4829-4843.
40. Volk DW, Austin MC, Pierri JN, Sampson AR, Lewis DA, (2000) Decreased glutamic acid decarboxylase67 messenger RNA expression in a subset of prefrontal cortical gamma-aminobutyric acid neurons in subjects with schizophrenia. Arch Gen Psychiatry 57: 237-245.
41. Hashimoto T, Volk DW, Eggan SM, Mirnics K, Pierri JN, et al. (2003) Gene expression deficits in a subclass of GABA neurons in the prefrontal cortex of subjects with schizophrenia. J Neurosci 23: 6315-6326.
42. Curley AA, Arion D, Volk DW, Asafu-Adjei JK, Sampson AR, et al. (2011) Cortical deficits of glutamic acid decarboxylase 67 expression in schizophrenia: clinical, protein, and cell type-specific features. Am J Psychiatry 168: 921-929.
43. Adams B, Moghaddam B, (1998) Corticolimbic dopamine neurotransmission is temporally dissociated from the cognitive and locomotor effects of phencyclidine. J Neurosci 18: 5545-5554.
44. Razoux F, Garcia R, Lena I, (2007) Ketamine, at a dose that disrupts motor behavior and latent inhibition, enhances prefrontal cortex synaptic efficacy and glutamate release in the nucleus accumbens. Neuropsychopharmacology 32: 719-727.
45. Ehrlichman RS, Gandal MJ, Maxwell CR, Lazarewicz MT, Finkel LH, et al. (2009) N-methyl-d-aspartic acid receptor antagonist-induced frequency oscillations in mice recreate pattern of electrophysiological deficits in schizophrenia. Neuroscience 158: 705-712.
46. Zarate CA Jr, Singh JB, Carlson PJ, Brutsche NE, Ameli R, et al. (2006) A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry 63: 856-864.
47. St Clair D, Blackwood D, Muir W, Carothers A, Walker M, et al. (1990) Association within a family of a balanced autosomal translocation with major mental illness. Lancet 336: 13-16.
48. Blackwood DH, Fordyce A, Walker MT, St Clair DM, Porteous DJ, et al. (2001) Schizophrenia and affective disorders-cosegregation with a translocation at chromosome 1q42 that directly disrupts brain-expressed genes: clinical and P300 findings in a family. Am J Hum Genet 69: 428-433.
49. Millar JK, Wilson-Annan JC, Anderson S, Christie S, Taylor MS, et al. (2000) Disruption of two novel genes by a translocation co-segregating with schizophrenia. Hum Mol Genet 9: 1415-1423.
50. Risbrough VB, Masten VL, Caldwell S, Paulus MP, Low MJ, et al. (2006) Differential contributions of dopamine D1, D2, and D3 receptors to MDMA-induced effects on locomotor behavior patterns in mice. Neuropsychopharmacology 31: 2349-2358.
51. Tanaka S, Young JW, Halberstadt AL, Masten VL, Geyer MA, (2012) Four factors underlying mouse behavior in an open field. Behav Brain Res 233: 55-61.